Selected research
Industry Research
Inhalation Sevoflurane Anaesthetic Agent Industry Research Report 2026
Market perspective
The global Inhalation Sevoflurane Anaesthetic Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Inhalation Sevoflurane Anaesthetic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Inhalation Sevoflurane Anaesthetic Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Inhalation Sevoflurane Anaesthetic Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Inhalation Sevoflurane Anaesthetic Agent include Maruishi, Piramal, PT Novell Pharmaceutical, Viatris, AbbVie and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Inhalation Sevoflurane Anaesthetic Agent market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inhalation Sevoflurane Anaesthetic Agent Market by Company
Maruishi
Piramal
PT Novell Pharmaceutical
Viatris
AbbVie
Baxter
Inhalation Sevoflurane Anaesthetic Agent Segment by Type
250ml/Bottle
120ml/Bottle
Other
Inhalation Sevoflurane Anaesthetic Agent Segment by Application
Hospital
Clinics
Other
Inhalation Sevoflurane Anaesthetic Agent Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation Sevoflurane Anaesthetic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation Sevoflurane Anaesthetic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation Sevoflurane Anaesthetic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Inhalation Sevoflurane Anaesthetic Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Inhalation Sevoflurane Anaesthetic Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Inhalation Sevoflurane Anaesthetic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 250ml/Bottle
- 120ml/Bottle
- Other
Applications
- Hospital
- Clinics
- Other
Companies covered
- Maruishi
- Piramal
- PT Novell Pharmaceutical
- Viatris
- AbbVie
- Baxter
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Inhalation Sevoflurane Anaesthetic Agent Market Size (2021-2032)
- 2.2.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales (2021-2032)
- 2.2.3 Global Inhalation Sevoflurane Anaesthetic Agent Market Average Price (2021-2032)
- 2.3 Inhalation Sevoflurane Anaesthetic Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 250ml/Bottle
- 2.3.3 120ml/Bottle
- 2.3.4 Other
- 2.4 Inhalation Sevoflurane Anaesthetic Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Inhalation Sevoflurane Anaesthetic Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Inhalation Sevoflurane Anaesthetic Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Inhalation Sevoflurane Anaesthetic Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Inhalation Sevoflurane Anaesthetic Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Inhalation Sevoflurane Anaesthetic Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Inhalation Sevoflurane Anaesthetic Agent, Product Type & Application
- 3.8 Global Manufacturers of Inhalation Sevoflurane Anaesthetic Agent, Established Date
- 3.9 Global Inhalation Sevoflurane Anaesthetic Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Maruishi
- 4.1.1 Maruishi Company Information
- 4.1.2 Maruishi Business Overview
- 4.1.3 Maruishi Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Maruishi Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.1.5 Maruishi Recent Developments
- 4.2 Piramal
- 4.2.1 Piramal Company Information
- 4.2.2 Piramal Business Overview
- 4.2.3 Piramal Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Piramal Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.2.5 Piramal Recent Developments
- 4.3 PT Novell Pharmaceutical
- 4.3.1 PT Novell Pharmaceutical Company Information
- 4.3.2 PT Novell Pharmaceutical Business Overview
- 4.3.3 PT Novell Pharmaceutical Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 PT Novell Pharmaceutical Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.3.5 PT Novell Pharmaceutical Recent Developments
- 4.4 Viatris
- 4.4.1 Viatris Company Information
- 4.4.2 Viatris Business Overview
- 4.4.3 Viatris Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Viatris Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.4.5 Viatris Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 Baxter
- 4.6.1 Baxter Company Information
- 4.6.2 Baxter Business Overview
- 4.6.3 Baxter Inhalation Sevoflurane Anaesthetic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Baxter Inhalation Sevoflurane Anaesthetic Agent Product Portfolio
- 4.6.5 Baxter Recent Developments
5 Global Inhalation Sevoflurane Anaesthetic Agent Market Scenario by Region
- 5.1 Global Inhalation Sevoflurane Anaesthetic Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Region: 2021-2032
- 5.2.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Region: 2021-2026
- 5.2.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Region: 2027-2032
- 5.3 Global Inhalation Sevoflurane Anaesthetic Agent Revenue by Region: 2021-2032
- 5.3.1 Global Inhalation Sevoflurane Anaesthetic Agent Revenue by Region: 2021-2026
- 5.3.2 Global Inhalation Sevoflurane Anaesthetic Agent Revenue by Region: 2027-2032
- 5.4 North America Inhalation Sevoflurane Anaesthetic Agent Market Facts & Figures by Country
- 5.4.1 North America Inhalation Sevoflurane Anaesthetic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Inhalation Sevoflurane Anaesthetic Agent Sales by Country (2021-2032)
- 5.4.3 North America Inhalation Sevoflurane Anaesthetic Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Inhalation Sevoflurane Anaesthetic Agent Market Facts & Figures by Country
- 5.5.1 Europe Inhalation Sevoflurane Anaesthetic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Inhalation Sevoflurane Anaesthetic Agent Sales by Country (2021-2032)
- 5.5.3 Europe Inhalation Sevoflurane Anaesthetic Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Inhalation Sevoflurane Anaesthetic Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Inhalation Sevoflurane Anaesthetic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Inhalation Sevoflurane Anaesthetic Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Inhalation Sevoflurane Anaesthetic Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Inhalation Sevoflurane Anaesthetic Agent Market Facts & Figures by Country
- 5.7.1 South America Inhalation Sevoflurane Anaesthetic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Inhalation Sevoflurane Anaesthetic Agent Sales by Country (2021-2032)
- 5.7.3 South America Inhalation Sevoflurane Anaesthetic Agent Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Inhalation Sevoflurane Anaesthetic Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Inhalation Sevoflurane Anaesthetic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Inhalation Sevoflurane Anaesthetic Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Inhalation Sevoflurane Anaesthetic Agent Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Type (2021-2032)
- 6.1.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Inhalation Sevoflurane Anaesthetic Agent Revenue by Type (2021-2032)
- 6.2.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Inhalation Sevoflurane Anaesthetic Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Inhalation Sevoflurane Anaesthetic Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Application (2021-2032)
- 7.1.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Inhalation Sevoflurane Anaesthetic Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Inhalation Sevoflurane Anaesthetic Agent Revenue by Application (2021-2032)
- 7.2.1 Global Inhalation Sevoflurane Anaesthetic Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Inhalation Sevoflurane Anaesthetic Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Inhalation Sevoflurane Anaesthetic Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Inhalation Sevoflurane Anaesthetic Agent Value Chain Analysis
- 8.1.1 Inhalation Sevoflurane Anaesthetic Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Inhalation Sevoflurane Anaesthetic Agent Production Mode & Process
- 8.2 Inhalation Sevoflurane Anaesthetic Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Inhalation Sevoflurane Anaesthetic Agent Distributors
- 8.2.3 Inhalation Sevoflurane Anaesthetic Agent Customers
9 Global Inhalation Sevoflurane Anaesthetic Agent Analyzing Market Dynamics
- 9.1 Inhalation Sevoflurane Anaesthetic Agent Industry Trends
- 9.2 Inhalation Sevoflurane Anaesthetic Agent Industry Drivers
- 9.3 Inhalation Sevoflurane Anaesthetic Agent Industry Opportunities and Challenges
- 9.4 Inhalation Sevoflurane Anaesthetic Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst